This profile was last updated on
Is this you? Claim your profile.
(150 Total References)
Mitchell H. Gold, MD - ...
Mitchell H. Gold, MD - Founder & Executive Chairman
In addition to his role at Alpine Biosciences, Dr. Gold serves as the managing partner of Alpine BioVentures, a healthcare focused hedge/venture fund.
Dr. Gold was previously the President and CEO of Dendreon, where he and his team secured FDA approval for Provenge, the world's first active cellular immunotherapy.
Mitchell H. Gold, MD - Founder and Executive Chairman
Cancer Research Institute ...
Cancer Research Institute Welcomes Mitchell H. Gold, M.D., to Board of Trustees
Mitchell H. Gold, M.D., has been elected to the Board of Trustees of the nonprofit Cancer Research Institute.
Dr. Gold is chairman, chief executive officer, and founder of Alpine Biosciences, a privately held, Seattle-based biotech company dedicated...
Mitchell H. Gold, MD
Dr. Mitchell H. Gold currently serves as executive chairman of Dendreon Corporation's Board of Directors.
Previously, he served as president and chief executive officer of Dendreon since 2003, as well as vice president of business development and as chief business officer when he joined Dendreon in 2001.
In April 2010 ? after more than 15 years of research and development, 15 clinical trials, and more than $1 billion raised ? Dendreon
received approval from the FDA
for the world's first autologous cellular immunotherapy, PROVENGE? (sipuleucel-T).
grew the company from having a market capitalization of $40 million to one of nearly $2 billion, establishing Dendreon
as one of the largest biotech companies in the world.
Prior to joining Dendreon, Dr. Gold previously served as vice president of business development and vice president of sales and marketing for Data Critical Corporation, a company engaged in wireless transmission of critical healthcare data, now a division of GE Medical.
Dr. Gold was the president, chief executive officer, and a co-founder of Elixis Corporation, a medical information systems company.
Dr. Gold currently serves on the board of the University of Washington/Fred Hutchinson Cancer Research Center Prostate Cancer Institute.
Dr. Gold received his B.S. from the University of Wisconsin-Madison and his M.D. from Rush Medical College in Chicago.
Dr. Gold was a resident physician in the Department of Urology at the University of Washington.
WBBA - Washington Biotechnology & Biomedical Association
• Mitchell H. Gold, MD, CEO, Dendreon Corporation
Dendreon Corporation - Board of Directors
Mitchell H. Gold M.D.
Dr. Gold has served as a member of our board of directors since May 2002.
He served as chairman of the Board of Directors from January 2012 until June 2012 and previously served as our President and Chief Executive Officer from January 2003 to January 2012.
Dr. Gold also served as our Vice President of Business Development from June 2001 to May 2002, and as our Chief Business Officer from May 2002 through December 2002.
From April 2000 to May 2001, Dr. Gold served as Vice President of Business Development and Vice President of Sales and Marketing for Data Critical Corporation, a company engaged in wireless transmission of critical healthcare data, now a division of GE Medical.
From 1995 to April 2000, Dr. Gold was the President and Chief Executive Officer, and a co-founder of Elixis Corporation, a medical information systems company.
From 1993 to 1998, Dr. Gold was a resident physician in the Department of Urology at the University of Washington.
Dr. Gold currently serves on the boards of the University of Washington/Fred Hutchinson Cancer Research Center Prostate Cancer Institute and the Washington Biotechnology and BioMedical Association and on the governing board of the Biotechnology Industry Organization.
Dr. Gold received a B.S. from the University of Wisconsin-Madison and an M.D. from Rush Medical College.